Republic of Moldova vs Zimbabwe: Average cost of multi drug-resistant tuberculosis treatment
Republic of Moldova
824 constant 2022 US$
in 2024
Zimbabwe
851 constant 2022 US$
in 2023
Republic of Moldova rank
60th
Zimbabwe rank
57th
Average cost of multi drug-resistant tuberculosis treatment over time
- Republic of Moldova
- Zimbabwe
How they compare
Zimbabwe currently reports 851 constant 2022 US$ against 824 constant 2022 US$ in Republic of Moldova, a difference of 27 constant 2022 US$.
Across all 7 years both countries report, Republic of Moldova has been ahead every year.
Republic of Moldova ranks 60th and Zimbabwe ranks 57th of 92 countries.
Republic of Moldova has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Republic of Moldova | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,572 constant 2022 US$ | 1,672 constant 2022 US$ | 900 constant 2022 US$ | Republic of Moldova |
| 2020s | 1,509 constant 2022 US$ | 696.25 constant 2022 US$ | 813 constant 2022 US$ | Republic of Moldova |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Republic of Moldova or Zimbabwe?
- Zimbabwe, at 851 constant 2022 US$ against 824 constant 2022 US$ in Republic of Moldova as of 2023.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Republic of Moldova and Zimbabwe?
- 27 constant 2022 US$, with Zimbabwe ahead.
- How many years of comparable data are there for Republic of Moldova and Zimbabwe?
- 7 years are reported by both, from 2017 to 2023.
- How do Republic of Moldova and Zimbabwe rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Republic of Moldova ranks 60th and Zimbabwe ranks 57th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.